Shirin Khambata‐Ford

Author

Bristol-Myers Squibb (United States)

Also Known As

S Khambata-Ford, S. Khambata-Ford, Shirin Khambata-Ford, Shirin Khambata‐Ford

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)Peter MacCallum Cancer Centre Flinders University Ottawa Hospital

About

Shirin Khambata‐Ford is an author at Bristol-Myers Squibb (United States) specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	696
2	Natural Sciences	1	1	27
3	Public Health	1	1	47
4	Biostatistics	1	1	47
5	Cell Biology	1	1	10

Shirin Khambata‐Ford

Publications

Citations

H-Index

Page 1

	Year	Citations
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, New England Journal of Medicine	2008	3.6K
Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Journal of Clinical Oncology	2007	1.1K
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, JAMA	2010	743
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Journal of Clinical Oncology	2006	536
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer Shirin Khambata‐Ford, Christopher Harbison, Lowell L. Hart, Journal of Clinical Oncology Patient SelectionImmunologyPathologyPotential Predictive MarkersTumor Biology	2010	268
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study Manfred Dietel, Rubén Salanova, Patrick Micke, Lung Cancer Tumor BiologyPrognostic BiomarkersReal-world PrevalenceMedicineCancer Cell Biology	2019	155
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer Joffre Baker, Debjani Dutta, Drew Watson, British Journal of Cancer	2011	108
Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms Marius Ilié, Shirin Khambata‐Ford, Christiane Copie‐Bergman, PLoS ONE	2017	97
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer Derek J. Jonker, Christos S. Karapetis, Christopher Harbison, British Journal of Cancer Epiregulin Gene ExpressionMedicineImmunologyPathologyColorectal Cancer	2013	94
Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients Marius Ilié, Jonathan Juco, Lingkang Huang, Cancer Cytopathology	2018	87

Page 1